Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 8, 2008, Pages 1889-1893

  Wu, Tzu Hua ^a   Chiu, Chih Chiang ^b,c,d   Shen, Winston W ^b,e   Lin, Fang Wei ^a   Wang, Li Hsuan ^a   Chen, Hsiang Yu ^a   Lu, Mong Liang ^b,e  

^a School of Pharmacy   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Dose concentration relationship; Olanzapine; Pharmacokinetics; Schizophrenia; Smoking behavior

Indexed keywords

OLANZAPINE;

ACCOMMODATION; ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING; SMOKING CESSATION;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BENZODIAZEPINES; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; TAIWAN; TIME FACTORS; YOUNG ADULT;

EID: 56449125381     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.08.022     Document Type: Article

References (45)

1. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37 (2004) 243-265
2. Baumann P., Hiemke C., Ulrich S., Gaertner I., Rao M.L., Eckermann G., et al. Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit 26 (2004) 167-170
3. Beasley Jr. C.M., Tollefson G.D., and Tran P.V. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 58 Suppl 10 (1997) 7-12
4. Berezhkovskiy L.M. On the determination of the time delay in reaching the steady state drug concentration in the organ compared to plasma. J Pharm Sci 96 (2007) 3432-3443
5. Bigos K.L., Pollock B.G., Coley K.C., Miller del D., Marder S.R., Aravagiri M., et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 48 (2008) 157-165
6. Binder R.L., Kazamatsuri H., Nishimura T., and McNiel D.E. Smoking and tardive dyskinesia. Biol Psychiatry 22 (1987) 1280-1282
7. Callaghan J.T., Bergstrom R.F., Ptak L.R., and Beasley C.M. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37 (1999) 177-193
8. Carrillo J.A., Herraiz A.G., Ramos S.I., Gervasini G., Vizcaino S., and Benitez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 23 (2003) 119-127
9. Chiu C.C., Lane H.Y., Huang M.C., Liu H.C., Jann M.W., Hon Y.Y., et al. Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol 44 (2004) 1385-1390
10. Chiu C.C., Lu M.L., Huang M.C., and Chen K.P. Heavy smoking, reduced olanzapine levels, and treatment effects: a case report. Ther Drug Monit 26 (2004) 579-581
11. Chong S.A., and Choo H.L. Smoking among Chinese patients with schizophrenia. Aust N Z J Psychiatry 30 (1996) 350-353
12. Dalack G.W., Healy D.J., and Meador-Woodruff J.H. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 155 (1998) 1490-1501
13. de Leon J., Becona E., Gurpegui M., Gonzalez-Pinto A., and Diaz F.J. The association between high nicotine dependence and severe mental illness may be consistent across countries. J Clin Psychiatry 63 (2002) 812-816
14. de Leon J., and Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 76 (2005) 135-157
15. Desai H.D., Seabolt J., and Jann M.W. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 15 (2001) 469-494
16. Gex-Fabry M., Balant-Gorgia A.E., and Balant L.P. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 25 (2003) 46-53
17. Gobburu J.V., and Holford N.H. Vz, the terminal phase volume: time for its terminal phase?. J Biopharm Stat 11 (2002) 373-375
18. Goff D.C., Henderson D.C., and Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149 (1992) 1189-1194
19. Haslemo T., Eikeseth P.H., Tanum L., Molden E., and Refsum H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 62 (2006) 1049-1053
20. Hughes J.R., and Frances R.J. How to help psychiatric patients stop smoking. Psychiatr Serv 46 (1995) 435-436
21. Kalow W., and Tang B.K. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49 (1991) 44-48
22. Kiang T.K., Ensom M.H., and Chang T.K. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106 (2005) 97-132
23. Lane H.Y., Liu H.C., VanDenBerg C.M., Su M.H., Jann M.W., and Chang W.H. Disposition of olanzapine in Chinese schizophrenic patients. Int J Clin Pharmacol Ther 38 (2000) 482-485
24. Liao D.L., Yang J.Y., Lee S.M., Chen H., and Tsai S.J. Smoking in chronic schizophrenic inpatients in Taiwan. Neuropsychobiology 45 (2002) 172-175
25. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol 17 (2002) 233-238
26. Melkersson K.I., Scordo M.G., Gunes A., and Dahl M.L. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry 68 (2007) 697-704
27. Olincy A., Young D.A., and Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 42 (1997) 1-5
28. Perry P.J., Argo T.R., Carnahan R.M., Lund B.C., Holman T.L., Ellingrod V.L., et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 25 (2005) 250-254
29. Perry P.J., Sanger T., and Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 17 (1997) 472-477
30. Ring B.J., Catlow J., Lindsay T.J., Gillespie T., Roskos L.K., Cerimele B.J., et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276 (1996) 658-666
31. Sacco K.A., Termine A., Seyal A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62 (2005) 649-659
32. Sachse C., Brockmoller J., Bauer S., and Roots I. Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47 (1999) 445-449
33. Samtani M.N., Schwab M., Nathanielsz P.W., and Jusko W.J. Area/moment and compartmental modeling of pharmacokinetics during pregnancy: applications to maternal/fetal exposures to corticosteroids in sheep and rats. Pharm Res 21 (2004) 2279-2292
34. Sathirakul K., Chan C., Teng L., Bergstrom R.F., Yeo K.P., and Wise S.D. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. Br J Clin Pharmacol 56 (2003) 184-187
35. Sevcik C. Parmacokinetic (PK) parameter Vss (volume in steady state) is superior or more reliable that Vz (the volume in the terminal state). J Biopharm Stat 16 (2006) 123-124
36. Skogh E., Reis M., Dahl M.L., Lundmark J., and Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 24 (2002) 518-526
37. Solak Z.A., Kabaroglu C., Cok G., Parildar Z., Bayindir U., Ozmen D., et al. Effect of different levels of cigarette smoking on lipid peroxidation, glutathione enzymes and paraoxonase 1 activity in healthy people. Clin Exp Med 5 (2005) 99-105
38. Theisen F.M., Haberhausen M., Schulz E., Fleischhaker C., Clement H.W., Heinzel-Gutenbrunner M., et al. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit 28 (2006) 750-759
39. Tollefson G.D., Beasley Jr. C.M., Tamura R.N., Tran P.V., and Potvin J.H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154 (1997) 1248-1254
40. Villard P.H., Herber R., Seree E.M., Attolini L., Magdalou J., and Lacarelle B. Effect of cigarette smoke on UDP-glucuronosyltransferase activity and cytochrome P450 content in liver, lung and kidney microsomes in mice. Pharmacol Toxicol 82 (1998) 74-79
41. Wen C.P., Levy D.T., Cheng T.Y., Hsu C.C., and Tsai S.P. Smoking behaviour in Taiwan, 2001. Tob Control 14 Suppl 1 (2005) i51-55
42. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 284 (2000) 3043-3045
43. Yassa R., Lal S., Korpassy A., and Ally J. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 22 (1987) 67-72
44. Zevin S., and Benowitz N.L. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 36 (1999) 425-438
45. Zhang X.Y., Tan Y.L., Zhou D.F., Haile C.N., Wu G.Y., Cao L.Y., et al. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology 32 (2007) 2020-2024